Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04880382
Other study ID # IB 2019-07
Secondary ID 2020-005562-34
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date August 27, 2021
Est. completion date August 2026

Study information

Verified date January 2024
Source Institut Bergonié
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Non-comparative multicentric randomized study to assess long-term benefit of PD-1 inhibition in NSCLC patients who experienced a response between 6 and 12 months after initiation of ICI (immune checkpoint inhibitor PD1/PDL-1 blockade therapy)


Description:

Two-arm, non-comparative, prospective, multicentric, randomized study for early discontinuation of immune checkpoint inhibitor PD1/PDL-1 blockade therapy in non-small cell lung cancer patients who achieved objective response between 6 and 12 months after treatment onset.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 80
Est. completion date August 2026
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histologically or cytologically confirmed non-small cell lung carcinoma (squamous or non squamous). 2. Locally advanced/unresectable or metastatic disease. 3. For non-squamous histology, tumor with no oncogenic addiction: no activating EGFR mutation, no ALK or ROS1 rearrangement, 4. Treatment with ICI (immune checkpoint inhibitor PD1/PDL-1 blockade therapy): 1. in first or second-line treatment as per market authorization. For patients in first line, ICI alone or ICI + chemotherapy, 2. start of ICI treatment 6 to 12 months (+/- 2 weeks) before registration. 5. At least one measurable lesion according to the RECIST v1.1 criteria before ICI treatment onset and confirmed by centralized review (lesion in previously irradiated filed can be considered as measurable if progressive at inclusion according to RECIST v1.1). At least one site of disease must be uni-dimensionally = 10 mm. 6. Patient with objective response according to RECIST v1.1 criteria at 6 months or more and less than 12 months after ICI treatment onset. Response must be confirmed by centralized review 7. At least one lesion that can be biopsied for research purpose. 8. Age = 18. 9. Performance status < 2. 10. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to registration. 11. Patient with a social security in compliance with the French law (Loi Jardé). 12. Patient must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. 13. Voluntarily signed and dated written informed consent prior to any study specific procedure. Exclusion Criteria: 1. Female who is pregnant or breast-feeding. 2. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study. 3. Hypersensitivity to one of the active substances or to one of the excipients 4. Any contraindication to pursue ICI treatment as per investigator judgement. 5. Previous enrolment in the present study. 6. Individual deprived of liberty or placed under legal guardianship.

Study Design


Intervention

Drug:
ICI treatment discontinuation
After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be discontinued. Patients will be followed as per standard mangement thereafter
ICI treatment continuation
After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be continued until disease progreession or unacceptable toxicity

Locations

Country Name City State
France Centre Hospitalier de la Côte Basque Bayonne
France Clinique Tivoli Ducos Bordeaux
France Institut Bergonie Bordeaux
France Polyclinique Bordeaux Nord Aquitaine Bordeaux
France Clinique Marzet Pau

Sponsors (1)

Lead Sponsor Collaborator
Institut Bergonié

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of the long-term benefit of PD-1 inhibition in NSCLC patients who experienced a response between 6 and 12 months after initiation of ICI Long-term benefit will be assessed in terms of progression-free rate (PFR) at 12 months after randomization, for each therapeutic strategy 12 months
Secondary Assessment of secondary resistance in NSCLC patients who experienced a response to PD1/PDL-1 inhibition The rate of patients who develop progression (as per RECIST v1.1) due to secondary resistance after obtaining a response to PD1/PDL-1 inhibition, independently for each therapeutic strategy 12 months
Secondary Duration of response independently for each therapeutic strategy Duration of response (DoR) defined as the time interval between the first response (complete or partial response as per RECIST v1.1) to the time of the first documentation of disease progression Throughout the treatment period, an expected average of 12 months
Secondary 1-year progression-free survival, independently for each therapeutic strategy Progression-free survival (PFS) defined as the time interval between the date of randomization and the date of progression or death, whichever occurs first. Progression will be determined according to RECIST v1.1 1 year
Secondary 2-year progression-free survival, independently for each therapeutic strategy Progression-free survival (PFS) defined as the time interval between the date of randomization and the date of progression or death, whichever occurs first. Progression will be determined according to RECIST v1.1 2 years
Secondary 1-year overall survival, independently for each therapeutic strategy Overall Survival (OS) defined as the time interval between the date of randomization and the date of death (of any cause) 1 year
Secondary 2-year overall survival, independently for each therapeutic strategy Overall Survival (OS) defined as the time interval between the date of randomization and the date of death (of any cause) 2 years
Secondary Safety profile, independently for each therapeutic strategy: Common Terminology Criteria for Adverse Events version 5 Toxicity graded using the Common Terminology Criteria for Adverse Events version 5 Throughout the treatment and follow-up period, an expected average of 12 months
Secondary • To describe retreatment for arm B-patients and subsequent systemic therapies for arm A-patients Number of patients retreated by ICI will be described in Arm B. Similarly, for arm A-patients, number of patients treated by subsequent systemic therapy will be described Throughout the treatment and follow-up period, an expected average of 12 months
Secondary Tumor immune cells levels Levels of immune cells in tumor will be measured by immunohistochemistry. At study onset (randomization) and at progression (throughout the treatment and follow-up period, an average of 12 months)
Secondary Blood cytokines levels Levels of cytokines in blood will be measured by ELISA At study onset (randomization) and at progression (throughout the treatment and follow-up period, an average of 12 months)
Secondary Blood lymphocytes levels Levels of lymphocytes in blood will be measured by flow cytometry At study onset (randomization) and at progression (throughout the treatment and follow-up period, an average of 12 months)
Secondary Blood kynurenine levels Levels of kynurenine in blood will be measured by ELISA At study onset (randomization) and at progression (throughout the treatment and follow-up period, an average of 12 months)
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT05898763 - TEIPP Immunotherapy in Patients With NSCLC Phase 1/Phase 2
Recruiting NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/Phase 2
Completed NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors Phase 2
Terminated NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06020989 - Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Phase 2
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Completed NCT03780010 - Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC Phase 1